Publicaciones en colaboración con investigadores/as de Stony Brook University (24)

2024

  1. Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery

    Journal of Thoracic Oncology, Vol. 19, Núm. 3, pp. 476-490

  2. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. The role of personal identity as a resource for college students during COVID-19

    Journal of American College Health

2022

  1. Role of EXO1 nuclease activity in genome maintenance, the immune response and tumor suppression in Exo1D173Amice

    Nucleic Acids Research, Vol. 50, Núm. 14, pp. 8093-8106

2021

  1. Digital acoustic surveillance for early detection of respiratory disease outbreaks in Spain: A protocol for an observational study

    BMJ Open, Vol. 11, Núm. 7

  2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  3. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study

    International Immunopharmacology, Vol. 90

  4. Pharoh lncrna regulates myc translation in hepatocellular carcinoma via sequestering tiar

    eLife, Vol. 10

  5. The association between self-perceived walking pace with the incidence of hypertension: the 'Seguimiento Universidad de Navarra' cohort

    Journal of hypertension, Vol. 39, Núm. 6, pp. 1188-1194

  6. The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD

    Clinical Imaging, Vol. 78, pp. 136-141

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Identification of resistance pathways specific to malignancy using organoid models of pancreatic cancer

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6742-6755

  3. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  4. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2018

  1. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis

    ESC Heart Failure, Vol. 5, Núm. 1, pp. 139-148

2017

  1. Risk for incident heart failure: A subject-level meta-analysis from the heart "OMics" in AGEing (HOMAGE) study

    Journal of the American Heart Association, Vol. 6, Núm. 5

  2. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: Association with baseline disease severity and subsequent outcome

    JAMA Cardiology, Vol. 2, Núm. 9, pp. 995-1006

2016

  1. Impact of surgery for stage IA non-smallcell lung cancer on patient quality of life

    Journal of Community and Supportive Oncology, Vol. 14, Núm. 1, pp. 37-44

2015

  1. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage

    Journal of the American Heart Association, Vol. 4, Núm. 12